Achillion Pharmaceuticals (ACHN) 2.83 $ACHN
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
PR Newswire - Mon Apr 14, 7:16AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Commit To Buy Achillion Pharmaceuticals At $2.50, Earn 30.7% Annualized Using Options
StockOptionsChannel.com - Mon Apr 07, 10:41AM CDT
Investors considering a purchase of Achillion Pharmaceuticals Inc. shares, but cautious about paying the going market price of $3.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
3 Biotechs Bucking the Downtrend
George Budwell, The Motley Fool - Motley Fool - Tue Mar 25, 10:30AM CDT
Mr. Market savaged the biotech sector yesterday. Specifically, 92% of small-caps were losers, 94% of mid-caps painted the tape red, and large caps saw a single winner, Gilead Sciences . Given the broad-based downtrend in the sector, I think it's...
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores
PR Newswire - Tue Mar 25, 10:24AM CDT
The US markets saw a negative sentiment on Monday, March 24, 2014, with the NASDAQ Composite closing at 4,226.89, down 1.18%, the Dow Jones Industrial Average ending the session at 16,276.69, down 0.16% and the S&P 500 edging 0.49% lower to finish the trading session at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. A number of stocks saw large movements, including Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Microvision Inc. (NASDAQ: MVIS), Miller Energy Resources Inc. (NYSE: MILL), and The Bon-Ton Stores Inc. (NASDAQ: BONT). Free technical research on ACHN, MVIS, MILL, and BONT can be downloaded upon signing up at:
Why Herbalife, Steel Partners Holdings, and Achillion Pharmaceuticals Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 24, 7:00PM CDT
Monday was an up-and-down day on Wall Street, as major stock market benchmarks moved on both sides of unchanged before settling down on the day. Biotech stocks weighed especially hard on the Nasdaq, but that didn't keep some stocks from scoring...
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Achillion Pharmaceuticals Inc. Shares Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 12:48PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a...
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
GlobeNewswire - Fri Mar 14, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two oral presentations were made at the 23 Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 (n=
including subjects who had Y93 mutations at baseline. A second oral presentation on ACH-3102 was made at APASL 2014 that discussed clinical virology and the lack of virologic breakthrough that was observed in the novel Phase 2 clinical trial evaluating ACH-3102 with ribavirin for patients with treatment-naïve genotype 1b HCV. Despite the presence of up to six linked mutations identified at baseline in the NS5A protein, ACH-3102, without the co-administration of interferon or a second direct-acting antiviral, was able to suppress viral replication with no virologic breakthrough observed during 12 weeks of treatment.
Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
Achillion Pharmaceuticals ' net loss widens to USD59.0m in 2013
M2 - Mon Mar 10, 7:41AM CDT
US-based biopharmaceutical company Achillion Pharmaceuticals (NasdaqGS :ACHN) announced on Friday a net loss of USD59.0m for the 12 months ended 31 December 2013.
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Fri Mar 07, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2013.
Achillion Hasn't Stopped Aching
at The Street - Tue Mar 04, 3:42PM CST
It's a mistake to buy these shares before any real announcement about when the new hepatitis-C drugs will come to market.
5 Stocks Gearing Up for Monster Short Squeezes
at The Street - Fri Feb 28, 7:12AM CST
These heavily shorted stocks could get squeezed higher on any positive catalyst
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Achillion Pharmaceuticals, Inc. (ACHN) Soars: Stock Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:51AM CST
Achillion Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 10% on the day.
Mattersight Announces Fourth Quarter 2013 Results
Marketwire - Wed Feb 12, 3:44PM CST
Mattersight Corporation (NASDAQ: MATR) today announced financial results for the fourth quarter ended December 31, 2013.
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 10, 5:00AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
Nigeria Tops AJC First Leg Qualifiers
by Orkula Shaagee - All Africa Global Media - Fri Jan 17, 3:38AM CST
Team Nigeria was in comfortable lead yesterday as the first leg of the 2014 African Junior Tennis Championship (AJC) qualifiers ended at the Abuja National Stadium yesterday.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys
PR Newswire - Mon Apr 14, 7:16AM CDT
On Friday, April 11, 2014, the NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones Industrial Average declined 0.89%, to finish the day at 16,026.75, and the S&P 500 closed at 1,815.69, down 0.95%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN, MDVN, MSTX and ATHX can be downloaded upon signing up at:
Commit To Buy Achillion Pharmaceuticals At $2.50, Earn 30.7% Annualized Using Options
StockOptionsChannel.com - Mon Apr 07, 10:41AM CDT
Investors considering a purchase of Achillion Pharmaceuticals Inc. shares, but cautious about paying the going market price of $3.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.
3 Biotech Stocks Under $10 to Trade
at The Street - Wed Mar 26, 5:00AM CDT
Keep your eye on these under-$10 biotech stocks.
3 Biotechs Bucking the Downtrend
George Budwell, The Motley Fool - Motley Fool - Tue Mar 25, 10:30AM CDT
Mr. Market savaged the biotech sector yesterday. Specifically, 92% of small-caps were losers, 94% of mid-caps painted the tape red, and large caps saw a single winner, Gilead Sciences . Given the broad-based downtrend in the sector, I think it's...
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores
PR Newswire - Tue Mar 25, 10:24AM CDT
The US markets saw a negative sentiment on Monday, March 24, 2014, with the NASDAQ Composite closing at 4,226.89, down 1.18%, the Dow Jones Industrial Average ending the session at 16,276.69, down 0.16% and the S&P 500 edging 0.49% lower to finish the trading session at 1,857.44. The losses were broad based as eight out of ten sectors ended the session in negative. A number of stocks saw large movements, including Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Microvision Inc. (NASDAQ: MVIS), Miller Energy Resources Inc. (NYSE: MILL), and The Bon-Ton Stores Inc. (NASDAQ: BONT). Free technical research on ACHN, MVIS, MILL, and BONT can be downloaded upon signing up at:
Why Herbalife, Steel Partners Holdings, and Achillion Pharmaceuticals Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 24, 7:00PM CDT
Monday was an up-and-down day on Wall Street, as major stock market benchmarks moved on both sides of unchanged before settling down on the day. Biotech stocks weighed especially hard on the Nasdaq, but that didn't keep some stocks from scoring...
This Week in Biotech: NW Bio Soars While Geron Goes Geronimo
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 15, 2:15PM CDT
With the SPDR S&P Biotech Index up 59% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Achillion Pharmaceuticals Inc. Shares Briefly Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 12:48PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Achillion Pharmaceuticals , a...
Achillion Announces Oral Presentations Given at APASL 2014 Detailing Clinical Activity of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV
GlobeNewswire - Fri Mar 14, 5:05AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two oral presentations were made at the 23 Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 in Brisbane, Australia. Updated Phase 2 clinical trial results evaluating a 150 mg loading dose followed by 50 mg once daily of ACH-3102 in combination with either once daily 200 mg or 400 mg of sovaprevir and twice daily ribavirin showed that 100% of patients achieved SVR12 (n=
including subjects who had Y93 mutations at baseline. A second oral presentation on ACH-3102 was made at APASL 2014 that discussed clinical virology and the lack of virologic breakthrough that was observed in the novel Phase 2 clinical trial evaluating ACH-3102 with ribavirin for patients with treatment-naïve genotype 1b HCV. Despite the presence of up to six linked mutations identified at baseline in the NS5A protein, ACH-3102, without the co-administration of interferon or a second direct-acting antiviral, was able to suppress viral replication with no virologic breakthrough observed during 12 weeks of treatment. Narrower-than-Expected Loss at Achillion, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
The share price of Achillion Pharmaceuticals fell slightly after the company announced its fourth-quarter results.
Achillion Pharmaceuticals ' net loss widens to USD59.0m in 2013
M2 - Mon Mar 10, 7:41AM CDT
US-based biopharmaceutical company Achillion Pharmaceuticals (NasdaqGS :ACHN) announced on Friday a net loss of USD59.0m for the 12 months ended 31 December 2013.
Achillion Reports 2013 Fourth Quarter and Year-End Financial Results
GlobeNewswire - Fri Mar 07, 5:05AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and twelve months ended December 31, 2013.
Achillion Hasn't Stopped Aching
at The Street - Tue Mar 04, 3:42PM CST
It's a mistake to buy these shares before any real announcement about when the new hepatitis-C drugs will come to market.
5 Stocks Gearing Up for Monster Short Squeezes
at The Street - Fri Feb 28, 7:12AM CST
These heavily shorted stocks could get squeezed higher on any positive catalyst
The 10 Most Heavily Shorted Bio-Pharma Stocks
at The Street - Mon Feb 24, 9:39AM CST
The No. 1 stock on this list has more than half its float short.
Achillion Pharmaceuticals, Inc. (ACHN) Soars: Stock Up 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 7:51AM CST
Achillion Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 10% on the day.
Mattersight Announces Fourth Quarter 2013 Results
Marketwire - Wed Feb 12, 3:44PM CST
Mattersight Corporation (NASDAQ: MATR) today announced financial results for the fourth quarter ended December 31, 2013.
Achillion to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Feb 10, 5:00AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
Nigeria Tops AJC First Leg Qualifiers
by Orkula Shaagee - All Africa Global Media - Fri Jan 17, 3:38AM CST
Team Nigeria was in comfortable lead yesterday as the first leg of the 2014 African Junior Tennis Championship (AJC) qualifiers ended at the Abuja National Stadium yesterday.
Stock Price Movements, FDA Applications, Appointments, and Clinical Study Updates - Research Report on Alere, ARCA, Achillion, Idenix Pharmaceuticals, and Receptos
PR Newswire - Mon Jan 13, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Alere Inc. (NYSE: ALR), ARCA biopharma, Inc. (NASDAQ: ABIO), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Receptos, Inc. (NASDAQ: RCPT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
